Changes in Serum Erythropoietin Levels during Chemotherapy for Lung Cancer
Yasuo Saijo(Ho Chi Minh City International University), Masakichi Motomiya(Tohoku University), Yuka Numata(Chugoku Rosai Hospital), Shuji Suzuki(Tokyo Institute of Technology), Yushi Nakai(Tohoku University), Shunichi Sugawara(Sendai Kousei Hospital), Junichi Saito
Cited by 7
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695